Montevideo, Feb 28 (Prensa Latina) The beginning of Phase III of clinical trials of two Cuban-made Covid-19 vaccine has made headlines in Uruguayan media in the last few days.
The three main television news programs broadcast an extensive report from the Havana-based Center for Genetic Engineering and Biotechnology (CIGB), and remarks by BioCubaFarma Business Group President Eduardo Martinez.
Caras y Caretas weekly displayed headline, photos and details in its current issue, highlighting that Cuba has technological platforms, professional experience, mastery of genetic engineering and ability to combine vaccine candidates.
Hence, Martinez emphasizes that with better immunogens, Cuba is making progress with four anti-Covid-19 vaccine candidates, Soberana 02 and Abdala (CIGB-66) in Phase III of clinical trial as of March 1, and Soberana 01 and Mambisa (CIGB-669) in Phase II.
With the announced upcoming event, Uruguayan news agency uy.press followed a news sequence that began a week ago with remarks by Cuban President Miguel Diaz-Canel on the willingness and capacity of Cuba’s pharmaceutical industry to produce 100 million doses of Soberana 02 vaccines.
The next day, the news agency reproduced an entire article published in The New York Times about that ‘Coronavirus vaccine nears final tests in Cuba.’
El Pais newspaper also echoed US media that highlighted Cuba is ‘on the brink of an extraordinary scientific achievement: the mass production of a coronavirus vaccine invented on the island.’
In one of two consecutive articles, La Republica stated the fact that ‘the small Caribbean island is ahead of many more developed countries in the race to find an effective vaccine may seem surprising.’